Sugammadex
- Generic Name
- Sugammadex
- Brand Names
- Bridion, Sugammadex Adroiq, Sugammadex Amomed, Sugammadex Fresenius Kabi, Sugammadex Mylan, Sugammadex Piramal
- Drug Type
- Small Molecule
- Chemical Formula
- C72H112O48S8
- CAS Number
- 343306-71-8
- Unique Ingredient Identifier
- 361LPM2T56
- Background
Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery. Rocuronium bromide and vecuronium bromide are neuromuscular blocking medications that cause temporary paralysis and are especially useful for general anesthesia, ventilation, or tracheal intubation that patients may require for surgery. Sugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. Sugammadex (brand name Bridion) is marketed by Merck Sharp and Dohme, and was approved by the United States FDA on December 15, 2015.
- Indication
Sugammadex is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide or vecuronium bromide in adults and pediatric patients ≥2 years old who are undergoing surgery.
- Associated Conditions
- Neuromuscular blockade caused by vecuronium bromide
Pilot Study on the Pharmacodynamics of Sugammadex in Morbidly Obese Patients: Reversal of Deep Neuromuscular Blockade
- First Posted Date
- 2013-05-16
- Last Posted Date
- 2013-05-17
- Lead Sponsor
- St. Antonius Hospital
- Target Recruit Count
- 25
- Registration Number
- NCT01855217
- Locations
- 🇳🇱
Sint Antonius Ziekenhuis, Nieuwegein, Netherlands
Reversal of Neuromuscular Blockade in Thoracic Surgical Patients
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2020-02-13
- Lead Sponsor
- NorthShore University HealthSystem
- Target Recruit Count
- 200
- Registration Number
- NCT01837498
- Locations
- 🇺🇸
NorthShore University HealthSystem, Evanston, Illinois, United States
Reversal With Sugammadex From Deep Neuromuscular Blockade Induced by Rocuronium in Children: Randomised Clinical Trial
- First Posted Date
- 2013-03-13
- Last Posted Date
- 2014-03-06
- Lead Sponsor
- Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
- Target Recruit Count
- 100
- Registration Number
- NCT01809886
- Locations
- 🇪🇸
Mª Dolores Cárceles Barón, El Palmar, Murcia, Spain
Efficacy and Safety of Sugammadex in Renal Diseased Patients
- Conditions
- Kidney Failure, ChronicNeuromuscular Blockade
- Interventions
- First Posted Date
- 2013-02-07
- Last Posted Date
- 2013-02-07
- Lead Sponsor
- Federal University of São Paulo
- Target Recruit Count
- 40
- Registration Number
- NCT01785758
- Locations
- 🇧🇷
Hospital do Rim e Hipertensão - Fundação Oswaldo Ramos, São Paulo, SP, Brazil
A Prospective, Randomized Controlled Trial Comparing Traditional Methods of Neuromuscular Block Reversal to Sugammadex for Extubation in the Operating Room in ASA 4 and 4E Patients
- Conditions
- Neuromuscular Blockade
- Interventions
- Drug: Atropine/Neostigmine
- First Posted Date
- 2013-01-04
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Hadassah Medical Organization
- Target Recruit Count
- 130
- Registration Number
- NCT01761552
- Locations
- 🇮🇱
Hadassah Medical Organization, Jerusalem, Israel
A Study Comparing the Use of Deep or Standard Neuromuscular Blockade in Combination With Low or Standard Insufflation Pressures in Participants Undergoing Laparoscopic Cholecystectomy (P07982)
- Conditions
- Gallbladder Disease
- Interventions
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2018-10-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 127
- Registration Number
- NCT01728584
- Locations
- 🇩🇪
Merck Sharp & Dohme GmbH, Haar, Germany
🇮🇹MSD Italia S.r.l., Rome, Italy
Comparison of Two Neuromuscular Anesthetics Reversal in Obese Patient Undergoing Bariatric Surgery
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2014-06-25
- Lead Sponsor
- Assuta Hospital Systems
- Target Recruit Count
- 40
- Registration Number
- NCT01631396
- Locations
- 🇮🇱
Assuta Medical Center, Tel Aviv, Israel
Comparative Study of Sugammadex Versus Neostigmine for Reversal of Neuromuscular Blockade in Morbidly Obese Patients
- First Posted Date
- 2012-06-27
- Last Posted Date
- 2012-06-27
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 120
- Registration Number
- NCT01629394
- Locations
- 🇬🇷
University of Patras, Department of Anesthesiology and Critical Care Medicine, Patras, Achaia, Greece
Recovery After Sugammadex(Propofol vs Sevoflurane)
- First Posted Date
- 2012-04-18
- Last Posted Date
- 2017-05-22
- Lead Sponsor
- Hopital Foch
- Target Recruit Count
- 71
- Registration Number
- NCT01579851
- Locations
- 🇫🇷
Hopital Foch, Suresnes, Ile de France, France
Sugammadex-dosing in Bariatric Patients
- Conditions
- Neuromuscular Blockade
- Interventions
- First Posted Date
- 2012-04-04
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- Central Hospital, Nancy, France
- Target Recruit Count
- 34
- Registration Number
- NCT01570179
- Locations
- 🇫🇷
CHU Strasbourg Hôpital Civil, Strasbourg, Alsace, France
🇫🇷CHU Nancy, Vandoeuvre-Les-Nancy, Lorraine, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.